Boston Scientific Co. (NYSE:BSX) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in shares of Boston Scientific Co. (NYSE:BSX) by 86.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,734 shares of the medical equipment provider’s stock after selling 198,927 shares during the quarter. SG Americas Securities LLC’s holdings in Boston Scientific were worth $2,659,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Triad Wealth Partners LLC acquired a new position in Boston Scientific during the 2nd quarter worth $26,000. First Foundation Advisors purchased a new position in Boston Scientific in the first quarter valued at about $25,000. Eagle Bay Advisors LLC grew its stake in Boston Scientific by 542.1% in the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 309 shares in the last quarter. Andra AP fonden purchased a new position in Boston Scientific in the second quarter valued at about $29,000. Finally, Lynx Investment Advisory bought a new stake in shares of Boston Scientific during the 2nd quarter worth about $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.86, for a total transaction of $585,594.38. Following the sale, the executive vice president now directly owns 34,748 shares in the company, valued at approximately $2,913,967.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 20,949 shares of company stock worth $1,673,685 in the last three months. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 0.2 %

Shares of BSX opened at $84.41 on Tuesday. The firm has a market capitalization of $123.84 billion, a price-to-earnings ratio of 70.92, a PEG ratio of 2.78 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The business’s fifty day moving average price is $80.07 and its two-hundred day moving average price is $75.91. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $85.26.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The firm had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. During the same period last year, the company earned $0.53 EPS. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. On average, analysts predict that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on BSX. Evercore ISI upped their price target on Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Canaccord Genuity Group upped their price target on Boston Scientific from $83.00 to $88.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Robert W. Baird upped their price target on Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft upped their price target on Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a report on Thursday, July 25th. Finally, BTIG Research upped their price target on Boston Scientific from $80.00 to $84.00 and gave the company a “buy” rating in a report on Monday, July 15th. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $87.10.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.